Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04592237
Title Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center

prostate small cell carcinoma

prostate carcinoma



Cabazitaxel + Carboplatin + Cetrelimab

Cetrelimab + Niraparib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST